Contineum Therapeutics, Inc. (CTNM) stock intrinsic value fair value estimate & owner earnings analysis

Contineum Therapeutics is a San Diego clinical-stage drug developer with no approved products and no product sales. Its value today rests on three things: about $236.6 million of cash and marketable securities at June 30, 2026 (roughly $6.29 per share on 37.6 million Class A and Class B shares), no borrowings, and two early-stage drug candidates. PIPE-791, which it owns outright, is an LPA1 blocker now in the PROPEL-IPF Phase 2 trial in idiopathic pulmonary fibrosis (about 324 patients, 26-week treatment, more than 55 sites in eight countries, started in early 2026); a small Phase 1b study in chronic pain in April 2026 met its safety goals with pain scores numerically better than placebo. PIPE-307 is licensed to Johnson & Johnson, which paid $50 million upfront in 2023 and owes up to about $1.0 billion in milestones plus royalties in the low-double-digit to high-teen percent range if it succeeds. The Phase 2 VISTA trial of PIPE-307 in relapsing multiple sclerosis missed its primary and secondary efficacy goals in November 2025; J&J finished enrolling 107 patients in the MOONLIGHT-1 depression trial in June 2026 and decides alone whether to keep developing the drug. Earnings record: the business has never produced ongoing cash earnings. The only profitable year, 2023, came from the one-time J&J upfront payment and is excluded. In 2024 and 2025 owner earnings (operating cash flow with working-capital swings removed, stock compensation charged as a real cost, and all equipment spending treated as upkeep) were losses of about $45 million ($2.35 per share) and $61 million ($2.19 per share); the median of those two years, a loss of about $2.27 per share, is the starting point. The loss grew about 34% in 2025 while the loss per share narrowed only because more shares were issued. Stripping out interest earned on the cash (valued separately below), the company used about $59 million of cash in 2025 and about $57 million a year in the first half of 2026 before stock compensation, and it guides that its cash lasts through mid-2029, which implies spending will rise as PROPEL-IPF enrolls. No year-one improvement is assumed: every case has spending at or above the current rate. How we value it: because nothing yet brings in revenue, the business is worth its cash less the cash its disclosed plan will consume. We give no value to trial success, J&J milestones or royalties, because each depends on results that have not happened; the J&J contract is real but pays only if PIPE-307 works, and PIPE-307's only completed efficacy trial failed. We value future stock awards at almost nothing because existing options (about 5.5 million at an average price near $9.40) are far above the per-share values below, so cash burn is measured before stock compensation. Cash is assumed to earn about 3.5%, in line with 2025. About $5 million of office lease obligations (the lease liability was $8.3 million at the end of 2025) is assumed to remain in mid-2029 and is deducted. There is no debt, so what the business is worth and what shareholders own are the same. Base case ($0.83 per share): spending averages about $70 million a year from mid-2026 to mid-2029, above today's rate as the IPF trial fills, and the programs produce no credited value. About $42 million would be left in mid-2029, $37 million after lease obligations, worth about $31 million today, or $0.83 per share. Bull case ($1.39 per share): spending rises only modestly, to about $62 million a year from today's roughly $57-59 million, as the IPF trial fills, leaving about $62 million after lease obligations in mid-2029, worth about $52 million today, or $1.39 per share. Bear case ($0.00 per share): the company spends its cash on the schedule it has itself guided, reaching roughly zero by mid-2029, and must raise new money before the IPF readout. Existing holders then have no claim on remaining cash, so the value is about zero; with no debt, the case is not carried below zero. What would make this wrong: a positive PROPEL-IPF readout (expected around 2029) or a positive MOONLIGHT-1 result that triggers J&J milestones would create value none of these cases credit; a decision to stop spending and return cash would lift every case toward the $6.29 per share of cash. On the other side, the active ingredient for PIPE-791 is made by a single contract manufacturer in China (WuXi AppTec), so a supply cut-off or U.S. restrictions on Chinese biotech suppliers could delay the IPF trial and raise costs.